
A new treatment for advanced prostate cancer has been shown to extend the lifespans of the affected men by as much as one year, researchers said Sunday.
The study involved 790 men who were diagnosed with metastatic prostate cancer, meaning the disease had spread beyond the prostate.
Advertisement
By adding the chemotherapy drug docetaxel to standard hormone therapy, known as androgen deprivation therapy (ADT), fewer patients died and many lived longer.
After 29 months, 136 men had died in the ADT alone group and 101 in the combination group.
The median, or midpoint, overall survival for the ADT group was 44 months, while those who also received docetaxel lived 57.6 months.
ADT is an effective therapy but eventually most patients become resistant to it, allowing the cancer to spread.
Some 30,000 men die of hormone-resistant prostate cancer each year in the United States.
"Hormone therapy has been a standard treatment for prostate cancer since the 1950s," said lead study author Christopher Sweeney of the Dana Farber Cancer Institute in Boston, Massachusetts.
"This is the first study to identify a strategy that prolongs survival in newly diagnosed metastatic prostate cancer," he added, describing the benefit as "substantial."
The research was presented at the American Society of Clinical Oncology annual conference.
"These results demonstrate how we can use 'old tools' in new, more powerful ways to improve and extend patients' lives," said ASCO president Clifford Hudis.
Source: AFP
The median, or midpoint, overall survival for the ADT group was 44 months, while those who also received docetaxel lived 57.6 months.
Advertisement
ADT is an effective therapy but eventually most patients become resistant to it, allowing the cancer to spread.
Some 30,000 men die of hormone-resistant prostate cancer each year in the United States.
"Hormone therapy has been a standard treatment for prostate cancer since the 1950s," said lead study author Christopher Sweeney of the Dana Farber Cancer Institute in Boston, Massachusetts.
"This is the first study to identify a strategy that prolongs survival in newly diagnosed metastatic prostate cancer," he added, describing the benefit as "substantial."
The research was presented at the American Society of Clinical Oncology annual conference.
"These results demonstrate how we can use 'old tools' in new, more powerful ways to improve and extend patients' lives," said ASCO president Clifford Hudis.
Source: AFP
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Men´s Health News

Men can have adverse effects on erectile dysfunction due to prolonged space travel and high amounts of galactic cosmic radiation.

Diagnostic lipid markers for metabolic syndrome and SCFAs correlate with interleukin immunoexpression in benign hyperplasia prostate tissue.

A combination of decitabine that targets loss of the gene RB1 and DS-7300a that targets the B7-H3 receptors effectively reduces advanced prostate tumor growth.

Research reveals a robust association between insecticide exposure and decreased sperm concentration in adult men globally.

Impact of fathers' mental well-being on child development remains a relatively uncharted territory and is explored by a recent study.